8LBA Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinicDarren Hodgson, M.J. O’Connor, Xinsheng Yin et al.|European Journal of Cancer|2014Cited by 0
466 Next generation sequencing of BRCA1 and BRCA2 genes in ovarian tumors captures all germline mutations and expands the potential treatment group for the PARP inhibitor olaparibKirsten M. Timms, Jerry S. Lanchbury, Chris Neff et al.|European Journal of Cancer|2015Cited by 0